ScripInsmed Incorporated , Structure Therapeutics, Inc. and Merus N.V. raised more than $1.5bn combined in recent follow-on public offerings (FOPOs), taking advantage of a spike in investor interest an
ScripWho: Akari Therapeutics/Peak Bio What: Two struggling, publicly traded biotechs will combine in an all-stock merger of equals. Why: The combined firm, which will boast a Phase III C5/LTB4 inhibit
In VivoA recent panel discussion hosted by Biopharma Excellence featured experts in biotech and the evolving regulatory environment to talk about the challenge of achieving statistical significance with nove
ScripOmeros Corporation ’s hopes of launching its investigational product, narsoplimab, as a treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) were reinforce